Table 2.
Prevalence of comorbidities
| IBS-C: 275 | FC: 549 | NRC: 54 | p-value1 | |
|---|---|---|---|---|
| Dyspepsia | 128 (46.5%) | 200 (36.4%) | 14 (25.9%)# | <0.005 |
| Depression/anxiety | 111 (40.4%) | 164 (29.9%)* | 9 (16.7%)** | <0.0005 |
| GERD | 98 (35.6%) | 167 (30.4%) | 8 (14.8%)## ### | <0.01 |
| Sleep disturbances | 87 (31.6%) | 141 (25.7%) | 13 (24.1%) | ns |
| Hypertension | 45 (16.4%) | 135 (24.6%)§ | 11 (20.4%) | <0.05 |
| Urinary disturbances | 52 (18.9%) | 115 (20.9%) | 8 (14.8%) | ns |
| Thyroid disease | 26 (9.4%) | 65 (11.8%) | 6 (11.1%) | ns |
| Vaginitis | 29 (10.5%) | 46 (8.4%) | 4 (7.4%) | ns |
| Dyspareunia | 30 (10.9%) | 38 (6.9%) | 4 (7.4%) | ns |
| Diabetes | 7 (2.5%) | 29 (5.3%) | 3 (5.6%) | ns |
| Fibromyalgia | 16 (5.8%) | 18 (3.3%) | - | ns |
| Other | 36 (13.1) | 56 (10.2%) | 7 (13%) | ns |
IBS-C irritable bowel syndrome with constipation, FC functional constipation, NRC patients do not accomplish Rome III criteria, GERD gastroesophageal reflux disease
1 p values are referred to the differences between IBS-C, FC and NRC groups, in particular
*p < 0.01 vs IBS-C; **p < 0.005 vs IBS-C; #p < 0.05 vs IBS-C and FC; ##p < 0.01 vs IBS-C
###p < 0.05 vs FC; §p < 0.05 vs IBS-C; ns: not statistically significant